Risk of bleeding not increased by sorafenib or sunitinib

The Lancet Oncology

Volumn 11, Issue 2, 2010, Pages 112-113

  Minor, David R ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; INTERFERON; PLACEBO; SORAFENIB; SUNITINIB;

BLEEDING; CANCER PATIENT; CLINICAL TRIAL; HUMAN; INCIDENCE; KIDNEY CANCER; LETTER; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; HEMORRHAGE; HUMANS; INDOLES; NEOPLASMS; PYRIDINES; PYRROLES; RISK FACTORS;

EID: 75249093377     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70366-3     Document Type: Letter

References (4)

1. Je Y., Schultz F.A., and Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10 (2009) 967-974
2. Escudier B., Eisen T., Stadler W., et al. Sorafenib in advanced renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
3. Nalluri S.R., Chu D., Keresztes R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. JAMA 300 (2008) 2277-2285
4. Chu D., and Wu S. Risk of venous thromboembolism with bevacizumab in cancer patients-reply. JAMA 301 (2009) 1435-1436